Glenmark Reaches $29M Deal In Generics Price-Fixing Case
Glenmark Pharmaceuticals Inc. and 48 states and territories have reached a $29.6 million settlement resolving allegations the company fixed prices in the generic pharmaceuticals market....To view the full article, register now.
Already a subscriber? Click here to view full article